Business News • PR NewsWire • Cequent Begins Chronic Toxicology Study with CEQ508, Lead Oncology tkRNAi Drug Candidate; Also Initiates First NHP Toxicology Study of Novartis-Optioned IBD Drug Candidate

Cequent Begins Chronic Toxicology Study with CEQ508, Lead Oncology tkRNAi Drug Candidate; Also Initiates First NHP Toxicology Study of Novartis-Optioned IBD Drug Candidate

Cequent Begins Chronic Toxicology Study with CEQ508, Lead Oncology tkRNAi Drug Candidate; Also Initiates First NHP Toxicology Study of Novartis-Optioned IBD Drug Candidate

CAMBRIDGE, Mass., April 15 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, has initiated a long-term (26-week) toxicology study of CEQ508 – the company's lead drug candidate based on it

View More : http://www.prnewswire.com/news-releases/cequent-begins-chronic-toxicology-study-with-ceq508-lead-oncology-tkrnai-drug-ca...

Releted News by prnewswire

Chemotherapy-Induced Neutropenia Can Cause Additional Burden and Risk for Cancer Patients, Pan-European Survey Reveals

Evan Kravitz Joins Eastern Pennsylvania Youth Soccer Association as Manager of Marketing and Communications

BNY Mellon Asset Servicing Introduces New Securities Lending Dashboard Reporting Capabilities

Cequent Begins Chronic Toxicology Study with CEQ508, Lead Oncology tkRNAi Drug Candidate; Also Initiates First NHP Toxicology Study of Novartis-Optioned IBD Drug Candidate